Pharmacodynamic Effects and Predictive Biomarkers of Janus Kinases (JAK)/Signal Transducer and Activator of Transcription (STAT) Inhibition With Ruxolitinib in Operable Head and Neck Cancer: a Window Trial
Latest Information Update: 26 Oct 2023
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Carcinoma; Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 19 Oct 2023 Status changed from recruiting to completed.
- 20 Sep 2023 Planned End Date changed from 30 Jun 2023 to 31 Oct 2024.
- 20 Sep 2023 Planned primary completion date changed from 30 Jun 2023 to 31 Oct 2024.